Abstract: Techniques for designing optical devices that can be manufactured in volume are disclosed. In an exemplary an optical assembly, to ensure that all collimators are on one side to facilitate efficient packaging, all collimators are positioned on both sides of a substrate. Thus one or more beam folding components are used to fold a light beam up and down through the collimators on top of the substrate and bottom of the substrate.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.

Abstract: This invention relates to a substrate and the application. In particular, this invention discloses a substrate which has at least one contact structure at least on one side and at least one contact structure at least on one surface of the substrate. The substrate includes a thermal insulation material comprising at least two materials selecting from a thermal energy reflecting material, a homogeneous foam material, a heterogeneous foam material, a skin material, a skeleton structured material, an electromagnetic wave shielding material. The substrate may be used to construct various articles with different features of energy saving, decoration and protection as well as simple installation for various applications.

Abstract: The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Abstract: The present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof: wherein A is of the formula: where Q, W, X, Y, and Z are defined herein. In a second embodiment, the present invention relates to pharmaceutical compositions comprising pro-drugs or pharmaceutically acceptable salts of the compounds of the present invention and the use thereof for treating autoimmune diseases or for the prevention of organ transplantation rejection in a subject. In a third embodiment, the present invention relates to processes for the production of novel cyclosporin analogs of the present invention.

Abstract: Improved designs of optical devices for processing optical signals with one or more specified wavelengths are disclosed. According to embodiment, a filter mirror assembly appears an “L” shape and provides a filtering function as well as a reflecting function. The filter mirror assembly is so mounted that a rotation thereof will not alter the optical path the beam positions of signals resulted from a rotation of the filter mirror assembly. To cancel or minimize a lateral shift introduced to a light beam going through an optical filter, an optical compensator is introduced and rotates oppositely whenever the optical filter rotates.

Abstract: In an information handling system, when a memory location is accessed and there is a bit error detected in that memory location then the memory location is logged into an error-log. The memory locations of the logged bit errors stored in the error-log are evaluated to determine whether there is one or more bit errors in a particular memory range, e.g., a contiguous range of memory locations. If there is one or more bit errors in a memory range, then that memory range may be hot ejected, e.g., disabled from use by the operating system. The bit error may be single bit error and/or multiple bit errors of a memory location.

Abstract: A thermally-enhanced cavity down ball grid array (CDBGA) package is provided. In one embodiment, the CDBGA package comprises a heat dissipating substrate having a heat spreader and a chip carrier, the chip carrier having a cavity therethrough to allow a chip to be attached to the heat spreader. A chip having an active surface and a corresponding back surface, has the back surface of the chip mounted on the heat spreader. A dummy chip is attached to the active surface of the chip. The dummy chip has a coefficient of thermal expansion approximately equal to the coefficient of thermal expansion of the chip. An encapsulant encapsulates the chip and portions of the dummy chip. Dummy chip 90 has a coefficient of thermal expansion (CTE) approximately equal to the coefficient of thermal expansion of the chip 40.

Abstract: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A 3D package has: a three-dimensional (3D) package substrate, a land grid array (LGA) or quad flat no-lead (QFN) package mounted on the 3D package substrate, the LGA or QFN package having an LGA or QFN die on a first side of an LGA or QFN package substrate, and a second die mounted directly on a second side of the LGA or QFN package substrate opposite the first side.

Abstract: The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: 1

Abstract: Novel anti-angiogenesis proteins and the nucleic acid sequences which encode them are disclosed by the present invention.

Abstract: Hexahydrotriazine compounds of the formula: 1

Abstract: A vehicle seat having an inflatable airbag with the trim cover overlying the airbag being reinforced in the region adjacent to the airbag and having a weakened zone formed by cutting the reinforcement to create a tear line for deployment of the airbag through the trim cover. The reinforcement reduces stretching of the trim cover during deployment of the airbag at locations surrounding the tear line such that the trim cover ruptures along the tear line to produce a predictable airbag deployment.